NCT04377620: A reported trial by Incyte Corporation
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04377620 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 24, 2020 |
| Completion date | Feb. 26, 2021 |
| Required reporting date | Feb. 26, 2022, midnight |
| Actual reporting date | Nov. 17, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |